Haemonetics Corporation
Haemonetics Corporation (HAE) Shares Outstanding — Overview
Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.
HAE · shares outstanding · updated Jun 10, 2026
Key metrics
as of Mar 28, 2026Shares Outstanding Growth Rate
CAGR · weighted avg basic sharesNegative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials
Shares outstanding history
Annual shares outstanding by year
Healthcare sector shares outstanding comparison
Shares Outstanding for similar companies or competitors in the Healthcare sector.
MRK
JNJ
ABBV
AZN
UNH
LLYHAE/company-screener · per-peer /income-statement · cache 86400s
Understanding Shares Outstanding
Basic · Diluted · FloatWhat Are Shares Outstanding? (Basic)
Haemonetics Corporation (HAE) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of March 28, 2026, Haemonetics Corporation reports 47.2M basic shares outstanding (weighted average).
Basic vs. Diluted Shares Outstanding
Haemonetics Corporation's basic shares outstanding (47.2M) represents currently issued shares. Diluted shares outstanding (47.4M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.37%.
Shares Outstanding vs. Float (Free Float)
Haemonetics Corporation's float is 44.9M (98.8% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.
ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.
FMP /income-statement · /shares-float · SEC EDGAR · USD
About shares outstanding & methodology
Haemonetics Corporation (HAE) shares outstanding history from 2007 to 2026. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.
Haemonetics Corporation shares outstanding for the fiscal year ending March 28, 2026 were 47.2M, a 6.26% decline year-over-year. Haemonetics Corporation FY 2026 shares outstanding were 47.2M, a -6.26% decline from FY 2025.
Haemonetics Corporation is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of -0.8% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.
Frequently asked questions
HAE shares outstanding · 4 questionsAs of March 28, 2026, Haemonetics Corporation (HAE) has approximately 47.2M basic shares outstanding and 47.4M diluted shares outstanding. This represents a -6.26% year-over-year change from FY 2025 (50.3M). Haemonetics Corporation's declining share count is primarily driven by its share buyback program. For the complete historical data table, see the history table above.
▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Haemonetics Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-10